Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 191
interventional 182
Observational 8
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 71
Drug|Other 41
Drug|Other|Procedure|Radiation 11
Biological|Drug|Other|Procedure|Radiation 8
Biological|Drug|Other 7
Biological|Drug|Procedure|Radiation 6
Drug|Procedure|Radiation 5
Biological|Drug 4
Drug|Other|Procedure 4
Biological|Drug|Other|Procedure 3
Biological|Other 3
Dietary Supplement|placebo 2
Drug|Procedure 2
Drug|Radiation 2
Other|Procedure 2
Biological 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|placebo|Procedure 1
Biological|Genetic|Other|Procedure 1
Device|Drug|Other|Procedure|Radiation 1
Dietary Supplement 1
Drug|Genetic|Other 1
Drug|Other|placebo|Procedure 1
Drug|placebo 1
Drug|placebo|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 135
United States|Canada 5
France 3
United States|Germany|Italy 3
Australia 2
Germany 2
Italy 2
Japan 2
United States|Australia|Canada 2
United States|France 2
United States|Italy 2
Australia|Austria|Belgium|Czechia|France|Israel|Japan|Spain 1
Canada 1
China 1
Denmark 1
Denmark|Norway|Sweden 1
Germany|Netherlands|United Kingdom 1
Sweden|United States|Belgium|Canada|Czechia|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Poland|Spain|United Kingdom 1
United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Australia|Canada|New Zealand 1
United States|Australia|Denmark|France|Germany|Italy|Spain|Sweden 1
United States|Austria|Belgium|Canada|France|Germany|Hungary|Italy|Korea, Republic of|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Czechia|France|Germany|Ireland|Israel|Italy|Netherlands|Spain 1
United States|Belgium|Canada|France|Germany|United Kingdom 1
United States|Belgium|France|Germany|Italy|Spain 1
United States|Canada|France|Spain 1
United States|Canada|New Zealand 1
United States|Canada|Puerto Rico 1
United States|Denmark 1
United States|France|Germany|Spain 1
United States|Korea, Republic of 1
United States|Spain 1

Sites per Study

Site_count Study_Count
1 95
2 14
3 12
4 11
5 3
6 3
7 2
8 2
9 3
10 3
11 5
12 1
13 1
16 1
17 2
18 1
20 1
21 1
24 2
25 1
27 1
31 1
35 2
36 1
38 1
50 1
53 1
54 1
59 1
82 1
87 1
96 1
179 1
234 1
242 1
298 1
513 1

Phase

Phase Study_Count
Phase 2 77
Phase 1 55
Phase 1/Phase 2 26
Phase 3 13
N/A 11

Number of Arms

Number_of_Arms Count_of_Studies
1 119
2 40
3 8
4 2
5 3
6 3
7 2
NA 5

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3
Min. 5.00000 4.00000 9.00 3.00000 67.0000
1st Qu. 14.00000 18.50000 32.50 29.75000 226.0000
Median 24.00000 36.00000 47.50 50.00000 408.0000
Mean 52.72727 41.56364 64.50 71.46053 459.7692
3rd Qu. 75.00000 60.00000 90.25 92.50000 517.0000
Max. 160.00000 200.00000 200.00 400.00000 1337.0000

Trial Group Type

group_type Group_Count
Experimental 245
Active Comparator 22
Placebo Comparator 5
NA 5
Other 3
No Intervention 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 125
Parallel Assignment 43
Crossover Assignment 5
Sequential Assignment 5
Factorial Assignment 2
NA 2

Primary Purpose

primary_purpose Study_Count
Treatment 165
Supportive Care 10
Prevention 3
Basic Science 2
Other 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 3
Austria|Croatia 1
France 1
Korea, Republic of 1
NA 1
Spain 1

Sites per Study

Site_count Study_Count
1 4
2 2
19 1
50 1

Enrollment Metrics

Measure Observational
Min 20.000
1st Qu 57.500
Median 181.000
Mean 395.625
3rd Qu 544.750
Max 1500.000

Observation Model

observational_model Study_Count
Case-Only 3
Cohort 3
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 4
Cross-Sectional 1
Other 1
Retrospective 1
NA 1

Registries

Studies by Country

Country Study_Count
Canada 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 5000
1st Qu 5000
Median 5000
Mean 5000
3rd Qu 5000
Max 5000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Other 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04266301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) https://ClinicalTrials.gov/show/NCT04266301 Recruiting Novartis 2027-08-26
NCT04139434 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) https://ClinicalTrials.gov/show/NCT04139434 Recruiting Newave Pharmaceutical Inc 2022-06-30
NCT03912064 A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT https://ClinicalTrials.gov/show/NCT03912064 Recruiting Dana-Farber Cancer Institute 2022-04-26
NCT03383575 Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT03383575 Recruiting M.D. Anderson Cancer Center 2022-02-28
NCT03588078 Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine https://ClinicalTrials.gov/show/NCT03588078 Active, not recruiting Groupe Francophone des Myelodysplasies 2020-05-01
NCT03333486 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer https://ClinicalTrials.gov/show/NCT03333486 Recruiting Roswell Park Cancer Institute 2022-09-06
NCT03326921 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03326921 Recruiting Fred Hutchinson Cancer Research Center 2023-12-16
NCT03306264 Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML https://ClinicalTrials.gov/show/NCT03306264 Active, not recruiting Astex Pharmaceuticals, Inc. 2019-03-31
NCT03289910 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT03289910 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT03268954 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) https://ClinicalTrials.gov/show/NCT03268954 Active, not recruiting Takeda 2020-11-30
NCT03263637 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies https://ClinicalTrials.gov/show/NCT03263637 Active, not recruiting AstraZeneca 2021-12-31
NCT03192397 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03192397 Recruiting Roswell Park Cancer Institute 2021-07-01
NCT03190915 Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT03190915 Recruiting National Cancer Institute (NCI) 2021-12-31
NCT03175978 IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT03175978 Recruiting IGF Oncology, LLC 2020-06-30
NCT03128034 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia https://ClinicalTrials.gov/show/NCT03128034 Recruiting Fred Hutchinson Cancer Research Center 2021-06-30
NCT03096782 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma https://ClinicalTrials.gov/show/NCT03096782 Recruiting M.D. Anderson Cancer Center 2020-10-31
NCT03072043 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT03072043 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-06-30
NCT03047993 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT03047993 Recruiting M.D. Anderson Cancer Center 2022-04-01
NCT03018223 Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT https://ClinicalTrials.gov/show/NCT03018223 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2018-12-15
NCT02960646 Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02960646 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT02935361 Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed https://ClinicalTrials.gov/show/NCT02935361 Recruiting University of Southern California 2020-11-02
NCT02907359 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs https://ClinicalTrials.gov/show/NCT02907359 Active, not recruiting Astex Pharmaceuticals, Inc. 2020-06-30
NCT02841540 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT02841540 Active, not recruiting Eisai Inc. 2020-12-01
NCT02807272 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02807272 Active, not recruiting Kura Oncology, Inc. 2021-01-15
NCT02727803 Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT02727803 Recruiting M.D. Anderson Cancer Center 2020-05-19
NCT02666950 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT02666950 Completed Mayo Clinic 2018-09-25
NCT02649764 Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT02649764 Active, not recruiting M.D. Anderson Cancer Center 2021-05-31
NCT02610777 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) https://ClinicalTrials.gov/show/NCT02610777 Active, not recruiting Takeda 2019-09-04
NCT02756572 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT02756572 Completed University of Washington 2020-03-01
NCT03404193 Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT03404193 Recruiting M.D. Anderson Cancer Center 2023-12-31
NCT02566304 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02566304 Recruiting Thomas Jefferson University 2020-07-23
NCT02556931 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies https://ClinicalTrials.gov/show/NCT02556931 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2021-07-31
NCT02553941 Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT02553941 Active, not recruiting University of California, Davis 2020-11-30
NCT02546284 Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) https://ClinicalTrials.gov/show/NCT02546284 Completed Humanigen, Inc. 2020-02-29
NCT02530034 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02530034 Recruiting M.D. Anderson Cancer Center 2022-01-31
NCT02397720 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02397720 Recruiting M.D. Anderson Cancer Center 2020-04-30
NCT02268253 Tagraxofusp (SL-401) in Patients With CMML or MF https://ClinicalTrials.gov/show/NCT02268253 Recruiting Stemline Therapeutics, Inc. 2021-07-31
NCT02210858 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT02210858 Completed National Cancer Institute (NCI) 2004-11-12
NCT02201329 Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT02201329 Completed Boehringer Ingelheim 2015-01-31
NCT02197676 A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response https://ClinicalTrials.gov/show/NCT02197676 Completed Groupe Francophone des Myelodysplasies 2016-02-06
NCT02190695 Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS https://ClinicalTrials.gov/show/NCT02190695 Active, not recruiting Fox Chase Cancer Center 2026-07-01
NCT02129101 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies https://ClinicalTrials.gov/show/NCT02129101 Completed Mayo Clinic 2016-12-31
NCT02121418 Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm https://ClinicalTrials.gov/show/NCT02121418 Completed University of Washington 2017-02-08
NCT01307579 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01307579 Active, not recruiting Children’s Oncology Group 2018-06-30
NCT01305200 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01305200 Completed Children’s Oncology Group 2015-06-30
NCT01300572 Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS https://ClinicalTrials.gov/show/NCT01300572 Completed Fred Hutchinson Cancer Research Center 2017-10-29
NCT03358719 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03358719 Active, not recruiting Roswell Park Cancer Institute 2020-02-27
NCT01926587 Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine https://ClinicalTrials.gov/show/NCT01926587 Active, not recruiting Onconova Therapeutics, Inc. 2020-09-30
NCT01894477 Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01894477 Active, not recruiting Fred Hutchinson Cancer Research Center 2017-01-09
NCT01885689 Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT01885689 Active, not recruiting City of Hope Medical Center 2021-12-31
NCT01872819 Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay https://ClinicalTrials.gov/show/NCT01872819 Completed University of Washington 2014-11-30
NCT01842646 Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) https://ClinicalTrials.gov/show/NCT01842646 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2016-01-31
NCT01834248 DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01834248 Completed Roswell Park Cancer Institute 2015-06-09
NCT01824693 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT01824693 Completed Children’s Oncology Group 2017-12-31
NCT01823198 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies https://ClinicalTrials.gov/show/NCT01823198 Active, not recruiting M.D. Anderson Cancer Center 2020-06-30
NCT01812252 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01812252 Recruiting Fred Hutchinson Cancer Research Center 2021-04-01
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01776723 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib https://ClinicalTrials.gov/show/NCT01776723 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2018-11-28
NCT01773395 GVAX vs. Placebo for MDS/AML After Allo HSCT https://ClinicalTrials.gov/show/NCT01773395 Active, not recruiting Dana-Farber Cancer Institute 2021-06-01
NCT01772420 Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT01772420 Recruiting Albert Einstein College of Medicine 2020-01-31
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01757639 Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01757639 Completed National Cancer Institute (NCI) 2016-12-31
NCT01736683 Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) https://ClinicalTrials.gov/show/NCT01736683 Completed Celgene 2018-04-30
NCT01664897 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01664897 Completed M.D. Anderson Cancer Center 2018-10-25
NCT01613976 A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients https://ClinicalTrials.gov/show/NCT01613976 Completed Novartis 2014-05-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01522976 Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT01522976 Active, not recruiting National Cancer Institute (NCI) 2015-06-01
NCT01519011 Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine https://ClinicalTrials.gov/show/NCT01519011 Completed Celgene 2012-12-31
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01404741 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) https://ClinicalTrials.gov/show/NCT01404741 Active, not recruiting Universitätsklinikum Hamburg-Eppendorf 2020-05-31
NCT01398462 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT01398462 Completed JW Pharmaceutical 2015-12-31
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01350947 A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT01350947 Completed University of Utah 2014-09-30
NCT01338987 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT01338987 Active, not recruiting National Institutes of Health Clinical Center (CC) 2017-12-01
NCT04160052 Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT04160052 Recruiting M.D. Anderson Cancer Center 2020-12-31
NCT03999723 Combining Active and Passive DNA Hypomethylation https://ClinicalTrials.gov/show/NCT03999723 Recruiting Rigshospitalet, Denmark 2023-03-31
NCT03922100 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML https://ClinicalTrials.gov/show/NCT03922100 Recruiting Nerviano Medical Sciences 2023-09-30
NCT03896269 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT03896269 Recruiting M.D. Anderson Cancer Center 2020-12-31
NCT03873311 Azacytidine + HAG Regimen in Elderly Patients With Myeloid Malignancy. https://ClinicalTrials.gov/show/NCT03873311 Recruiting Shenzhen Second People’s Hospital 2021-12-01
NCT03814005 A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment https://ClinicalTrials.gov/show/NCT03814005 Active, not recruiting Takeda 2020-10-05
NCT03813186 Effect of Food on Blood Levels of ASTX727 https://ClinicalTrials.gov/show/NCT03813186 Completed Astex Pharmaceuticals, Inc. 2019-06-14
NCT03746041 A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT03746041 Recruiting University of Rochester 2021-11-01
NCT03734601 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT03734601 Active, not recruiting Stanford University 2020-11-30
NCT03722407 Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion https://ClinicalTrials.gov/show/NCT03722407 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-05-01
NCT03683433 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation https://ClinicalTrials.gov/show/NCT03683433 Recruiting M.D. Anderson Cancer Center 2021-09-20
NCT03682029 Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies https://ClinicalTrials.gov/show/NCT03682029 Recruiting Rigshospitalet, Denmark 2020-12-01
NCT03672539 Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT03672539 Recruiting M.D. Anderson Cancer Center 2020-06-30
NCT03670966 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT03670966 Recruiting Fred Hutchinson Cancer Research Center 2023-09-01
NCT03613532 Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN https://ClinicalTrials.gov/show/NCT03613532 Recruiting Dana-Farber Cancer Institute 2020-10-01
NCT03515512 IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03515512 Recruiting Massachusetts General Hospital 2021-05-31
NCT03493646 Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 https://ClinicalTrials.gov/show/NCT03493646 Recruiting Kirby Institute 2020-12-31
NCT01251627 Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT01251627 Completed Fondazione Italiana Sindromi Mielodisplastiche Onlus 2011-12-31
NCT01235117 Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT01235117 Completed National Cancer Institute (NCI) 2012-12-31
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01169012 PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias https://ClinicalTrials.gov/show/NCT01169012 Completed UNC Lineberger Comprehensive Cancer Center 2012-04-30
NCT01165996 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT01165996 Completed Case Comprehensive Cancer Center 2011-12-31
NCT01139970 Veliparib and Temozolomide in Treating Patients With Acute Leukemia https://ClinicalTrials.gov/show/NCT01139970 Active, not recruiting National Cancer Institute (NCI) 2014-03-21
NCT01101880 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm https://ClinicalTrials.gov/show/NCT01101880 Completed University of Washington 2013-06-30
NCT01098084 Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) https://ClinicalTrials.gov/show/NCT01098084 Completed Groupe Francophone des Myelodysplasies 2009-06-30
NCT01083706 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01083706 Completed Fred Hutchinson Cancer Research Center 2013-12-31
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT01048034 Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) https://ClinicalTrials.gov/show/NCT01048034 Completed Nordic MDS Group 2012-08-31
NCT01020539 Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia https://ClinicalTrials.gov/show/NCT01020539 Active, not recruiting Columbia University 2011-07-20
NCT00988715 Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00988715 Completed Fred Hutchinson Cancer Research Center 2015-01-31
NCT00946647 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). https://ClinicalTrials.gov/show/NCT00946647 Completed Novartis 2019-04-29
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00860574 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT00860574 Completed Fred Hutchinson Cancer Research Center 2013-02-28
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia https://ClinicalTrials.gov/show/NCT00843882 Active, not recruiting National Cancer Institute (NCI) 2019-07-08
NCT01831232 Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT01831232 Completed Fred Hutchinson Cancer Research Center 2015-02-28
NCT00809250 Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00809250 Active, not recruiting Dana-Farber Cancer Institute 2011-05-31
NCT01892371 Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT01892371 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial https://ClinicalTrials.gov/show/NCT03878524 Recruiting OHSU Knight Cancer Institute 2022-02-27
NCT01928537 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine https://ClinicalTrials.gov/show/NCT01928537 Completed Onconova Therapeutics, Inc. 2017-06-29
NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts https://ClinicalTrials.gov/show/NCT01241500 Completed Onconova Therapeutics, Inc. 2018-10-03
NCT02472691 Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT https://ClinicalTrials.gov/show/NCT02472691 Completed Heinrich-Heine University, Duesseldorf 2020-04-23
NCT02367456 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients https://ClinicalTrials.gov/show/NCT02367456 Active, not recruiting Pfizer 2020-01-29
NCT02029950 Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT02029950 Active, not recruiting National Cancer Institute (NCI) 2020-07-04
NCT01629082 Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01629082 Completed National Institutes of Health Clinical Center (CC) 2015-10-27
NCT04093570 An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) https://ClinicalTrials.gov/show/NCT04093570 Enrolling by invitation Astex Pharmaceuticals, Inc. 2021-03-31
NCT03862157 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03862157 Recruiting M.D. Anderson Cancer Center 2024-01-01
NCT00761722 Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma https://ClinicalTrials.gov/show/NCT00761722 Completed Celgene 2016-04-06
NCT00744536 Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS https://ClinicalTrials.gov/show/NCT00744536 Completed Sunnybrook Health Sciences Centre 2012-01-31
NCT00719836 A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies https://ClinicalTrials.gov/show/NCT00719836 Completed S*BIO 2012-01-31
NCT00666588 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00666588 Completed National Cancer Institute (NCI) 2012-12-31
NCT00589316 Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00589316 Active, not recruiting Fred Hutchinson Cancer Research Center 2016-10-01
NCT00588991 Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00588991 Active, not recruiting National Cancer Institute (NCI) 2014-02-01
NCT00528983 Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00528983 Completed Celgene 2013-07-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00462605 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00462605 Completed National Cancer Institute (NCI) 2011-03-31
NCT00451048 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT00451048 Completed National Cancer Institute (NCI) 2011-09-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00397813 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00397813 Completed Fred Hutchinson Cancer Research Center 2017-09-30
NCT00392353 Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00392353 Active, not recruiting National Cancer Institute (NCI) 2021-06-30
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00381550 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00381550 Completed National Cancer Institute (NCI) 2011-03-31
NCT00357708 Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases https://ClinicalTrials.gov/show/NCT00357708 Completed National Cancer Institute (NCI) 2009-10-31
NCT00357305 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00357305 Completed National Cancer Institute (NCI) 2011-11-30
NCT00351975 Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases https://ClinicalTrials.gov/show/NCT00351975 Completed National Cancer Institute (NCI) 2013-03-31
NCT00313586 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00313586 Completed National Cancer Institute (NCI) 2013-07-31
NCT00299156 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00299156 Completed M.D. Anderson Cancer Center 2012-12-31
NCT00283114 A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00283114 Completed Seattle Genetics, Inc. 2010-01-31
NCT00255346 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) https://ClinicalTrials.gov/show/NCT00255346 Completed M.D. Anderson Cancer Center 2017-03-03
NCT00171912 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes https://ClinicalTrials.gov/show/NCT00171912 Completed Novartis 2012-01-31
NCT00167219 Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) https://ClinicalTrials.gov/show/NCT00167219 Recruiting Masonic Cancer Center, University of Minnesota 2020-12-31
NCT00136409 A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) https://ClinicalTrials.gov/show/NCT00136409 Completed Dana-Farber Cancer Institute 2005-08-31
NCT00119366 Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00119366 Completed Fred Hutchinson Cancer Research Center 2014-08-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00101179 MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00101179 Completed National Cancer Institute (NCI) 2011-04-20
NCT00098423 Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00098423 Completed National Cancer Institute (NCI) 2009-05-31
NCT00096122 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00096122 Completed National Cancer Institute (NCI) 2006-09-30
NCT00095797 XK469R in Treating Patients With Refractory Hematologic Cancer https://ClinicalTrials.gov/show/NCT00095797 Completed National Cancer Institute (NCI) 2007-03-31
NCT00087204 Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00087204 Completed National Cancer Institute (NCI) 2007-01-31
NCT00084916 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase https://ClinicalTrials.gov/show/NCT00084916 Completed National Cancer Institute (NCI) 2007-03-31
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00005942 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy https://ClinicalTrials.gov/show/NCT00005942 Completed National Cancer Institute (NCI) 2000-12-31
NCT00079313 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00079313 Completed National Institutes of Health Clinical Center (CC) 2006-12-30
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00015990 Thalidomide in Treating Patients With Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00015990 Completed National Cancer Institute (NCI) 2007-02-28
NCT00008177 Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00008177 Completed Fred Hutchinson Cancer Research Center 2009-03-21
NCT00005845 Tipifarnib in Treating Patients With Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00005845 Completed National Cancer Institute (NCI) 2009-09-30
NCT00067808 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) https://ClinicalTrials.gov/show/NCT00067808 Completed M.D. Anderson Cancer Center 2009-05-31
NCT00052832 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT00052832 Completed University of Wisconsin, Madison 2005-07-31
NCT00039416 Imatinib Mesylate in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00039416 Completed National Cancer Institute (NCI) 2007-08-31
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00027820 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00027820 Completed Fred Hutchinson Cancer Research Center 2004-09-30
NCT00025662 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS https://ClinicalTrials.gov/show/NCT00025662 Completed National Institutes of Health Clinical Center (CC) 2008-02-29
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00025038 Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT00025038 Completed National Cancer Institute (NCI) 2007-10-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00012376 Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer https://ClinicalTrials.gov/show/NCT00012376 Completed National Cancer Institute (NCI) 2010-01-31
NCT00006363 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00006363 Completed National Cancer Institute (NCI) 2005-06-30
NCT00002798 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00002798 Completed National Cancer Institute (NCI) 2006-09-30
NCT00038675 Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate https://ClinicalTrials.gov/show/NCT00038675 Completed M.D. Anderson Cancer Center 2013-11-30
NCT00038051 Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies https://ClinicalTrials.gov/show/NCT00038051 Completed M.D. Anderson Cancer Center 2013-02-28
NCT00052520 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00052520 Completed Fred Hutchinson Cancer Research Center 2011-04-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03363399 Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT03363399 Completed University Hospital, Grenoble 2018-09-06
NCT02891551 An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands https://ClinicalTrials.gov/show/NCT02891551 Completed Celgene 2016-06-30
NCT02085798 Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) https://ClinicalTrials.gov/show/NCT02085798 Completed Celgene 2015-08-31
NCT01595295 Registry on Hypomethylating Agents in Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT01595295 Recruiting Arbeitsgemeinschaft medikamentoese Tumortherapie 2020-06-30
NCT01464047 Korean Post-marketing Surveillance for Sprycel® https://ClinicalTrials.gov/show/NCT01464047 Completed Bristol-Myers Squibb 2015-08-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01146210 Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01146210 Completed Children’s Oncology Group 2016-05-31
NCT03526666 Ascorbic Acid Levels in MDS, AML, and CMML Patients https://ClinicalTrials.gov/show/NCT03526666 Completed Van Andel Research Institute 2018-10-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry https://ClinicalTrials.gov/show/NCT02760238 Recruiting University Health Network, Toronto 2025-10-31